Fairfield, CT, United States of America

David E Puleo

This inventor holds 1 USPTO granted patent and 9 published patent applications. Top assignee: Halda Therapeutics Opco, Inc.. Active years: 2026.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: David E Puleo: Innovator in Heterobifunctional Compounds

Introduction

David E Puleo is a notable inventor based in Fairfield, CT (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that can be used to treat diseases such as cancer. His innovative work has the potential to impact the medical community positively.

Latest Patents

David E Puleo holds a patent for "Heterobifunctional compounds and their use in treating disease." This invention provides heterobifunctional compounds and pharmaceutical compositions that can be utilized in the treatment of various diseases, including cancer. His patent represents a significant advancement in therapeutic options available for patients.

Career Highlights

David is currently associated with Halda Therapeutics Opco, Inc., where he continues to work on groundbreaking research and development in the pharmaceutical sector. His expertise and dedication to innovation have positioned him as a valuable asset in his field.

Collaborations

David has collaborated with notable colleagues, including James John Mousseau and Katherine J Kayser-Bricker. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

David E Puleo's contributions to the field of pharmaceuticals through his innovative patents and collaborations highlight his commitment to advancing medical science. His work in developing heterobifunctional compounds is a testament to the impact that dedicated inventors can have on healthcare.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…